A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
To read the full story
Related Article
- Novartis Says Only 3,000 Pollen Allergy Patients Used Xolair This Season, Less than 10% of Re-Pricing Line
May 10, 2021
- 7 Generic API Specifications Subject to New Rule to Address Unreasonable Price Rises
March 6, 2020
- 3 Drugs Earn Post-Launch “True Clinical Utility” Premium; Forxiga Price Flat, Rises for Canaglu and Praluent
March 5, 2020
- Price Maintenance Premium Granted to 335 APIs/555 Products; Novartis Top PMP Earner
March 5, 2020
- With 80%-Plus Gx Rates, Many One-Time Blockbusters Might Be In for Earlier “G1” Price Cuts
March 5, 2020
- Xolair’s Re-Pricing Decided, but Regulators and Novartis Were at Odds over Patient Projections
March 2, 2020
- Nasal Steroid Used as “Reference Drug” for Xolair in Special Re-Pricing
January 23, 2020
- Japan’s Special Re-Pricing Rules to Hit 17 Drugs in April; Potentially Big Slash for Keytruda, Lixiana
January 22, 2020
- Xolair Faces New Special Re-Pricing Rule; Keytruda, Lixiana Caught by Huge-Seller Price Slash
January 21, 2020
- Xolair’s Use Would Be Limited to 1-3% of Pollen Allergy Patients in Japan: Specialist
January 20, 2020
REGULATORY
- Two Oral Drugs Found to Exceed ADI for Red No. 3, MHLW Reports
July 28, 2025
- PMDA Launches Advisory Program for Academia, Startups Developing New Modalities
July 28, 2025
- MSD’s 21-Valent Pneumococcal Shot Nears Japan Approval; Male Use of Silgard 9 Cleared
July 25, 2025
- Santen’s Glaucoma Drug, Taisho’s Insomnia Med Up for Panel Review on July 31
July 25, 2025
- MHLW Calls for Ongoing Nitrosamine Risk Controls after Self-Inspections
July 24, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…